Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 23Thoracic 3Breast 2Gynecologic 1Gastrointestinal 1CNS 1

Conditions

Carcinoma, Hepatocellular 86Colorectal Neoplasms 81Stomach Neoplasms 59Pancreatic Neoplasms 56Carcinoma, Non-Small-Cell Lung 46Melanoma 34Carcinoma, Renal Cell 28Neoplasm Metastasis 25Esophageal Neoplasms 24Neoplasms 23Colonic Neoplasms 22Squamous Cell Carcinoma of Head and Neck 21Carcinoma, Transitional Cell 20Liver Neoplasms 19Ovarian Neoplasms 17Adenocarcinoma Of Esophagus 17Esophageal Squamous Cell Carcinoma 16Triple Negative Breast Neoplasms 15Rectal Neoplasms 15Breast Neoplasms 14Biliary Tract Neoplasms 14Uterine Cervical Neoplasms 13Lung Neoplasms 12Cholangiocarcinoma 12Carcinoma, Merkel Cell 12Head and Neck Neoplasms 10Gastrointestinal Neoplasms 9Small Cell Lung Carcinoma 8Prostatic Neoplasms 8Endometrial Neoplasms 8

Interventions

Cyclophosphamide 3pembrolizumab 2Melphalan 2utomilumab 1tislelizumab 1spartalizumab 1niraparib 1montanide ISA 51 1entinostat 1binimetinib 1Toll-Like Receptor 1 1Rose Bengal 1Protein Kinase C 1Nivolumab 1Interleukin-2 1Injections 1Imatinib Mesylate 1Cryosurgery 1Crizotinib 1Blood Specimen Collection 1Bevacizumab 1Amplified Fragment Length Polymorphism Analysis 1ADI PEG20 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uveal Melanoma × Nivolumab × Gastrointestinal × Clear all
NCT04336241 2026-02-27

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

Replimune, Inc.

Phase 1 Active not recruiting
36 enrolled
BreastDermatologicGastrointestinalThoracic

Uveal Melanoma, Breast Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡